US20020068326A1 - Papillomavirus vaccines - Google Patents

Papillomavirus vaccines Download PDF

Info

Publication number: US20020068326A1
Authority: US; United States
Prior art keywords: hpv; protein; bpv; antibody; vaccine
Prior art date: 1992-06-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

US08/473,228

Other languages

English (en)

Inventor

C. Richard Schlegel

A. Bennett Jensen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-06-25

Filing date

1995-06-07

Publication date

2002-06-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25416951&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20020068326(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-06-07 Application filed by Individual filed Critical Individual

1995-06-07 Priority to US08/473,228 priority Critical patent/US20020068326A1/en

2002-06-06 Publication of US20020068326A1 publication Critical patent/US20020068326A1/en

Status Abandoned legal-status Critical Current

Links

229960002566 papillomavirus vaccine Drugs 0.000 title 1
210000002845 virion Anatomy 0.000 claims abstract description 68
229960005486 vaccine Drugs 0.000 claims abstract description 40
208000009608 Papillomavirus Infections Diseases 0.000 claims abstract description 18
241001465754 Metazoa Species 0.000 claims abstract description 15
101710121996 Hexon protein p72 Proteins 0.000 claims abstract description 10
101710125418 Major capsid protein Proteins 0.000 claims abstract description 10
108090000623 proteins and genes Proteins 0.000 claims description 126
102000004169 proteins and genes Human genes 0.000 claims description 112
241001631646 Papillomaviridae Species 0.000 claims description 77
238000000034 method Methods 0.000 claims description 50
208000022361 Human papillomavirus infectious disease Diseases 0.000 claims description 39
241000701806 Human papillomavirus Species 0.000 claims description 35
230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 claims description 34
239000013598 vector Substances 0.000 claims description 25
239000000203 mixture Substances 0.000 claims description 18
239000012634 fragment Substances 0.000 claims description 17
230000000890 antigenic effect Effects 0.000 claims description 12
241000701447 unidentified baculovirus Species 0.000 claims description 9
230000002163 immunogen Effects 0.000 claims description 8
239000008194 pharmaceutical composition Substances 0.000 claims description 7
230000002265 prevention Effects 0.000 claims description 6
108091003079 Bovine Serum Albumin Proteins 0.000 claims description 3
239000003443 antiviral agent Substances 0.000 claims description 3
238000002651 drug therapy Methods 0.000 claims description 3
229940098773 bovine serum albumin Drugs 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims description 2
230000001225 therapeutic effect Effects 0.000 claims description 2
230000003472 neutralizing effect Effects 0.000 abstract description 20
102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract description 8
108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract description 8
238000011282 treatment Methods 0.000 abstract description 7
208000036142 Viral infection Diseases 0.000 abstract description 3
238000003745 diagnosis Methods 0.000 abstract description 3
208000003154 papilloma Diseases 0.000 abstract description 3
230000001681 protective effect Effects 0.000 abstract description 3
230000009385 viral infection Effects 0.000 abstract description 3
241000388186 Deltapapillomavirus 4 Species 0.000 description 102
235000018102 proteins Nutrition 0.000 description 92
210000004027 cell Anatomy 0.000 description 74
241000709701 Human poliovirus 1 Species 0.000 description 40
241000283973 Oryctolagus cuniculus Species 0.000 description 38
208000015181 infectious disease Diseases 0.000 description 37
239000002245 particle Substances 0.000 description 32
206010028980 Neoplasm Diseases 0.000 description 25
238000006386 neutralization reaction Methods 0.000 description 24
241000283690 Bos taurus Species 0.000 description 23
244000309466 calf Species 0.000 description 20
241000700605 Viruses Species 0.000 description 18
238000003556 assay Methods 0.000 description 18
230000003612 virological effect Effects 0.000 description 18
201000011510 cancer Diseases 0.000 description 17
230000009257 reactivity Effects 0.000 description 17
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 16
239000002953 phosphate buffered saline Substances 0.000 description 16
210000002966 serum Anatomy 0.000 description 16
241001529936 Murinae Species 0.000 description 14
210000000234 capsid Anatomy 0.000 description 13
101150075239 L1 gene Proteins 0.000 description 12
238000002255 vaccination Methods 0.000 description 12
241000701814 Bovine papillomavirus type 2 Species 0.000 description 11
208000031513 cyst Diseases 0.000 description 11
230000002458 infectious effect Effects 0.000 description 11
238000002965 ELISA Methods 0.000 description 10
108700026244 Open Reading Frames Proteins 0.000 description 10
230000003902 lesion Effects 0.000 description 10
210000003491 skin Anatomy 0.000 description 10
108090000565 Capsid Proteins Proteins 0.000 description 9
102100023321 Ceruloplasmin Human genes 0.000 description 9
206010011732 Cyst Diseases 0.000 description 9
108020004414 DNA Proteins 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
238000001514 detection method Methods 0.000 description 9
238000010790 dilution Methods 0.000 description 9
239000012895 dilution Substances 0.000 description 9
239000000427 antigen Substances 0.000 description 8
108091007433 antigens Proteins 0.000 description 8
102000036639 antigens Human genes 0.000 description 8
230000001605 fetal effect Effects 0.000 description 8
201000010153 skin papilloma Diseases 0.000 description 8
241000282412 Homo Species 0.000 description 7
230000001419 dependent effect Effects 0.000 description 7
238000011161 development Methods 0.000 description 7
230000000521 hyperimmunizing effect Effects 0.000 description 7
238000000338 in vitro Methods 0.000 description 7
239000013612 plasmid Substances 0.000 description 7
241000699670 Mus sp. Species 0.000 description 6
208000000260 Warts Diseases 0.000 description 6
108020001507 fusion proteins Proteins 0.000 description 6
102000037865 fusion proteins Human genes 0.000 description 6
239000012133 immunoprecipitate Substances 0.000 description 6
238000001890 transfection Methods 0.000 description 6
-1 47Sc Chemical compound 0.000 description 5
241000701822 Bovine papillomavirus Species 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
208000019065 cervical carcinoma Diseases 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
238000010166 immunofluorescence Methods 0.000 description 5
238000001114 immunoprecipitation Methods 0.000 description 5
210000002510 keratinocyte Anatomy 0.000 description 5
229940126619 mouse monoclonal antibody Drugs 0.000 description 5
210000004940 nucleus Anatomy 0.000 description 5
239000000047 product Substances 0.000 description 5
230000010076 replication Effects 0.000 description 5
230000009466 transformation Effects 0.000 description 5
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
241000283707 Capra Species 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
241000238631 Hexapoda Species 0.000 description 4
239000012083 RIPA buffer Substances 0.000 description 4
150000001413 amino acids Chemical group 0.000 description 4
230000005875 antibody response Effects 0.000 description 4
239000000969 carrier Substances 0.000 description 4
238000010367 cloning Methods 0.000 description 4
229940088598 enzyme Drugs 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000013604 expression vector Substances 0.000 description 4
239000000284 extract Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
238000009396 hybridization Methods 0.000 description 4
230000028802 immunoglobulin-mediated neutralization Effects 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
230000003278 mimic effect Effects 0.000 description 4
238000010369 molecular cloning Methods 0.000 description 4
239000002773 nucleotide Substances 0.000 description 4
125000003729 nucleotide group Chemical group 0.000 description 4
238000012545 processing Methods 0.000 description 4
230000001105 regulatory effect Effects 0.000 description 4
230000000405 serological effect Effects 0.000 description 4
241000894007 species Species 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
206010059313 Anogenital warts Diseases 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
108700031454 Bovine papillomavirus L1 Proteins 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
101000958041 Homo sapiens Musculin Proteins 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
241000276498 Pollachius virens Species 0.000 description 3
101710172711 Structural protein Proteins 0.000 description 3
108020005202 Viral DNA Proteins 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
210000003679 cervix uteri Anatomy 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
201000004306 epidermodysplasia verruciformis Diseases 0.000 description 3
230000009841 epithelial lesion Effects 0.000 description 3
239000011521 glass Substances 0.000 description 3
102000046949 human MSC Human genes 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
230000028993 immune response Effects 0.000 description 3
230000036039 immunity Effects 0.000 description 3
238000003119 immunoblot Methods 0.000 description 3
238000011081 inoculation Methods 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
210000004877 mucosa Anatomy 0.000 description 3
229940023143 protein vaccine Drugs 0.000 description 3
239000000758 substrate Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
206010003445 Ascites Diseases 0.000 description 2
206010008263 Cervical dysplasia Diseases 0.000 description 2
206010008342 Cervix carcinoma Diseases 0.000 description 2
108020004638 Circular DNA Proteins 0.000 description 2
230000004543 DNA replication Effects 0.000 description 2
241000701808 Deltapapillomavirus 2 Species 0.000 description 2
206010058314 Dysplasia Diseases 0.000 description 2
241000341655 Human papillomavirus type 16 Species 0.000 description 2
241000701831 Human papillomavirus type 1a Species 0.000 description 2
102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
102000004195 Isomerases Human genes 0.000 description 2
108090000769 Isomerases Proteins 0.000 description 2
101710128836 Large T antigen Proteins 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
244000247617 Teramnus labialis var. labialis Species 0.000 description 2
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
241000251539 Vertebrata <Metazoa> Species 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
201000010881 cervical cancer Diseases 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000010276 construction Methods 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
239000003599 detergent Substances 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
210000000981 epithelium Anatomy 0.000 description 2
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
230000013595 glycosylation Effects 0.000 description 2
238000006206 glycosylation reaction Methods 0.000 description 2
230000005745 host immune response Effects 0.000 description 2
210000004408 hybridoma Anatomy 0.000 description 2
206010020718 hyperplasia Diseases 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
229940127121 immunoconjugate Drugs 0.000 description 2
238000011534 incubation Methods 0.000 description 2
238000002955 isolation Methods 0.000 description 2
238000002372 labelling Methods 0.000 description 2
230000004807 localization Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 2
229960000907 methylthioninium chloride Drugs 0.000 description 2
210000004400 mucous membrane Anatomy 0.000 description 2
230000009826 neoplastic cell growth Effects 0.000 description 2
230000001613 neoplastic effect Effects 0.000 description 2
108091008819 oncoproteins Proteins 0.000 description 2
102000027450 oncoproteins Human genes 0.000 description 2
230000008520 organization Effects 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
239000013641 positive control Substances 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
238000001243 protein synthesis Methods 0.000 description 2
ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
238000011160 research Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
239000000523 sample Substances 0.000 description 2
238000012216 screening Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
230000014616 translation Effects 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
RMBMWXHVTXYPQN-UHFFFAOYSA-N 1-[3-[(1-hydroxy-2,5-dioxopyrrolidin-3-yl)methyl]phenyl]pyrrole-2,5-dione Chemical compound O=C1N(O)C(=O)CC1CC1=CC=CC(N2C(C=CC2=O)=O)=C1 RMBMWXHVTXYPQN-UHFFFAOYSA-N 0.000 description 1
GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
108010000239 Aequorin Proteins 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
102000013142 Amylases Human genes 0.000 description 1
108010065511 Amylases Proteins 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
102000015790 Asparaginase Human genes 0.000 description 1
201000006935 Becker muscular dystrophy Diseases 0.000 description 1
208000037663 Best vitelliform macular dystrophy Diseases 0.000 description 1
102100026189 Beta-galactosidase Human genes 0.000 description 1
108700031455 Bovine papillomavirus L2 Proteins 0.000 description 1
208000009458 Carcinoma in Situ Diseases 0.000 description 1
102100035882 Catalase Human genes 0.000 description 1
108010053835 Catalase Proteins 0.000 description 1
108010049048 Cholera Toxin Proteins 0.000 description 1
102000009016 Cholera Toxin Human genes 0.000 description 1
101710094648 Coat protein Proteins 0.000 description 1
208000000907 Condylomata Acuminata Diseases 0.000 description 1
229920001076 Cutan Polymers 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
101150082674 E2 gene Proteins 0.000 description 1
108090000371 Esterases Proteins 0.000 description 1
IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
102100022624 Glucoamylase Human genes 0.000 description 1
108010015776 Glucose oxidase Proteins 0.000 description 1
239000004366 Glucose oxidase Substances 0.000 description 1
108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
241000701828 Human papillomavirus type 11 Species 0.000 description 1
241000701585 Human papillomavirus type 15 Species 0.000 description 1
241001428582 Human papillomavirus type 6 Species 0.000 description 1
101100428605 Human papillomavirus type 6b L2 gene Proteins 0.000 description 1
108010020056 Hydrogenase Proteins 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
108010059724 Micrococcal Nuclease Proteins 0.000 description 1
101710157639 Minor capsid protein Proteins 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
108020004711 Nucleic Acid Probes Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
241000609499 Palicourea Species 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
206010033724 Papilloma viral infections Diseases 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
108010053210 Phycocyanin Proteins 0.000 description 1
108010004729 Phycoerythrin Proteins 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
239000004365 Protease Substances 0.000 description 1
101710136297 Protein VP2 Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
108010046334 Urease Proteins 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
108070000030 Viral receptors Proteins 0.000 description 1
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
229960004373 acetylcholine Drugs 0.000 description 1
DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
108010004469 allophycocyanin Proteins 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
235000019418 amylase Nutrition 0.000 description 1
229940025131 amylases Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
229960003272 asparaginase Drugs 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
JLQUFIHWVLZVTJ-UHFFFAOYSA-N carbosulfan Chemical compound CCCCN(CCCC)SN(C)C(=O)OC1=CC=CC2=C1OC(C)(C)C2 JLQUFIHWVLZVTJ-UHFFFAOYSA-N 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
230000010307 cell transformation Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008614 cellular interaction Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229930002875 chlorophyll Natural products 0.000 description 1
235000019804 chlorophyll Nutrition 0.000 description 1
239000001752 chlorophylls and chlorophyllins Substances 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
206010016629 fibroma Diseases 0.000 description 1
239000012530 fluid Substances 0.000 description 1
ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
229940116332 glucose oxidase Drugs 0.000 description 1
235000019420 glucose oxidase Nutrition 0.000 description 1
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
230000036541 health Effects 0.000 description 1
244000144980 herd Species 0.000 description 1
230000002390 hyperplastic effect Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000003365 immunocytochemistry Methods 0.000 description 1
238000010820 immunofluorescence microscopy Methods 0.000 description 1
238000003125 immunofluorescent labeling Methods 0.000 description 1
230000002621 immunoprecipitating effect Effects 0.000 description 1
238000013383 initial experiment Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
208000024312 invasive carcinoma Diseases 0.000 description 1
SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
150000002540 isothiocyanates Chemical class 0.000 description 1
230000000155 isotopic effect Effects 0.000 description 1
239000010410 layer Substances 0.000 description 1
125000005647 linker group Chemical group 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
229940049920 malate Drugs 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
230000006740 morphological transformation Effects 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
239000013642 negative control Substances 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
238000012758 nuclear staining Methods 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
239000002853 nucleic acid probe Substances 0.000 description 1
150000007523 nucleic acids Chemical group 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920009537 polybutylene succinate adipate Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
150000004032 porphyrins Chemical class 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
210000005000 reproductive tract Anatomy 0.000 description 1
238000012552 review Methods 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
239000002356 single layer Substances 0.000 description 1
238000005549 size reduction Methods 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000008685 targeting Effects 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000012876 topography Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
231100000167 toxic agent Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
230000005945 translocation Effects 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
230000009447 viral pathogenesis Effects 0.000 description 1
208000020938 vitelliform macular dystrophy 2 Diseases 0.000 description 1
238000001262 western blot Methods 0.000 description 1
239000002023 wood Substances 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

US08/473,228 1992-06-25 1995-06-07 Papillomavirus vaccines Abandoned US20020068326A1 (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
US08/473,228 US20020068326A1 (en)	1992-06-25	1995-06-07	Papillomavirus vaccines

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US90310992A	1992-06-25	1992-06-25
US21650694A	1994-03-22	1994-03-22
US08/473,228 US20020068326A1 (en)	1992-06-25	1995-06-07	Papillomavirus vaccines

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
US21650694A Continuation	1992-06-25	1994-03-22

Publications (1)

Publication Number	Publication Date
US20020068326A1 true US20020068326A1 (en)	2002-06-06

Family

ID=25416951

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
US08/473,228 Abandoned US20020068326A1 (en)	1992-06-25	1995-06-07	Papillomavirus vaccines
US08/764,926 Expired - Fee Related US8012679B1 (en)	1992-06-25	1996-12-16	Papillomavirus vaccines

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
US08/764,926 Expired - Fee Related US8012679B1 (en)	1992-06-25	1996-12-16	Papillomavirus vaccines

Country Status (12)

Country	Link
US (2)	US20020068326A1 (fr)
EP (2)	EP1835029A1 (fr)
AT (1)	ATE380871T1 (fr)
AU (1)	AU697743C (fr)
DE (9)	DE122007000101I1 (fr)
DK (1)	DK0647140T3 (fr)
ES (1)	ES2294778T3 (fr)
FR (1)	FR07C0073I2 (fr)
LU (8)	LU91395I2 (fr)
NL (8)	NL300317I1 (fr)
PT (1)	PT647140E (fr)
WO (1)	WO1994000152A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8628784B2 (en) *	1998-10-16	2014-01-14	Glaxosmithkline Biologicals S.A.	Adjuvant systems and vaccines

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2279020T3 (es)	1991-07-19	2007-08-16	The University Of Queensland	Vacuna contra el papilomavirus humano.
US5437951A (en) *	1992-09-03	1995-08-01	The United States Of America As Represented By The Department Of Health And Human Services	Self-assembling recombinant papillomavirus capsid proteins
US8062642B1 (en)	1993-03-09	2011-11-22	University Of Rochester	Production of papillomavirus capsid protein and virus-like particles
US6153201A (en) *	1993-03-09	2000-11-28	University Of Rochester	Oral immunization with papillomavirus virus-like particles
DE4415743C2 (de) *	1994-05-04	1996-10-10	Deutsches Krebsforsch	Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
CN1152935A (zh) *	1994-05-16	1997-06-25	麦克公司	乳头状瘤病毒疫苗
US5888516A (en) *	1994-05-16	1999-03-30	Merck & Co. Inc.	Recombinant papillomavirus vaccines
AUPM566794A0 (en) *	1994-05-17	1994-06-09	University Of Queensland, The	Process and product
AU683564B2 (en) *	1994-05-17	1997-11-13	University Of Queensland, The	Recombinant papilloma virus L1
RU2177999C2 (ru) *	1994-09-22	2002-01-10	Мерк Энд Ко., Инк.	Экспрессирующий вектор (варианты)
EP1728800A1 (fr)	1994-10-07	2006-12-06	Loyola University Of Chicago	Particules semblables au virus du papillome, protéines de fusion et leur procédé de production
US5820870A (en) *	1995-03-22	1998-10-13	Merck & Co., Inc.	Recombinant human papillomavirus type 18 vaccine
IL117459A (en) *	1995-03-22	2005-11-20	Merck & Co Inc	Dna encoding human papillomavirus type 18
US5840306A (en) *	1995-03-22	1998-11-24	Merck & Co., Inc.	DNA encoding human papillomavirus type 18
US6908615B1 (en)	1996-03-18	2005-06-21	Merck & Co., Inc.	DNA encoding human papilloma virus type 18
GB9621091D0 (en)	1996-10-09	1996-11-27	Fondation Pour Le Perfectionem	Attenuated microorganisms strains and their uses
EP1000157A1 (fr) *	1997-07-03	2000-05-17	University Technology Corporation	Compositions renfermant des capsomeres de papillomavirus humain homogene, leurs procedes de production et leurs procedes d'utilisation en tant qu'agents diagnostiques, prophylactiques ou therapeutiques
US6228368B1 (en)	1997-10-06	2001-05-08	Loyola University Of Chicago	Papilloma virus capsomere formulations and method of use
US7182947B2 (en)	1998-02-20	2007-02-27	Medigene Ag	Papillomavirus truncated L1 protein and fusion protein constructs
US7494658B2 (en)	1998-02-20	2009-02-24	Medigene Ag	Papilloma virus truncated L1 protein and fusion protein constructs
CA2229955C (fr)	1998-02-20	2003-12-09	Medigene Gmbh	Formulations de vaccins contenant des capsomeres de papillomavirus; methodes d'utilisation
US20020039584A1 (en)	1998-02-20	2002-04-04	Medigene Ag	Papilloma virus capsomere vaccine formulations and methods of use
US6926897B1 (en)	1998-03-24	2005-08-09	Medigene Aktiengesellschaft	Medicament for the avoidance or treatment of papillomavirus-specific tumour
US6242176B1 (en)	1998-07-13	2001-06-05	Loyola University Of Chicago	Papillomavirus cellular receptor
US6692752B1 (en)	1999-09-08	2004-02-17	Smithkline Beecham Biologicals S.A.	Methods of treating human females susceptible to HSV infection
GB0109297D0 (en)	2001-04-12	2001-05-30	Glaxosmithkline Biolog Sa	Vaccine
CA2457804C (fr)	2001-08-13	2012-10-16	University Of Rochester	Immunisation transcutanee contre le papillomavirus avec un virus de type papillomavirus
GB0206360D0 (en) *	2002-03-18	2002-05-01	Glaxosmithkline Biolog Sa	Viral antigens
ES2356154T3 (es)	2003-07-21	2011-04-05	Transgene S.A.	Citoquinas multifuncionales.
TWI457133B (zh)	2005-12-13	2014-10-21	Glaxosmithkline Biolog Sa	新穎組合物
US20090181078A1 (en)	2006-09-26	2009-07-16	Infectious Disease Research Institute	Vaccine composition containing synthetic adjuvant
SI2068918T1 (sl)	2006-09-26	2012-09-28	Infectious Disease Res Inst	Si - ep sestavek za cepljenje, ki vsebuje sintetiäśna pomagala
HUE031411T2 (en)	2007-03-02	2017-07-28	Glaxosmithkline Biologicals Sa	New Methods and Preparations
JP5726727B2 (ja)	2008-05-26	2015-06-03	カディラ・ヘルスケア・リミテッド	麻疹−ヒトパピローマ混合ワクチン
GB0815872D0 (en)	2008-09-01	2008-10-08	Pasteur Institut	Novel method and compositions
GB0820822D0 (en)	2008-11-13	2008-12-24	Inst Catala D Oncologia	Novel product and processes
US20120115207A1 (en) *	2009-04-03	2012-05-10	Deutsches Krebsforschungszentrum	Enhanced production of papillomavirus-like particles with a modified baculovirus expression system
EP2437753B1 (fr)	2009-06-05	2016-08-31	Infectious Disease Research Institute	Adjuvants lipidiques synthétiques à base de glucopyranosyle et compositions de vaccin les contenant
WO2011026111A1 (fr)	2009-08-31	2011-03-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Distribution par voie orale d'un vaccin au gros intestin pour induire une immunité mucosale
WO2011127360A1 (fr)	2010-04-08	2011-10-13	University Of Pittsburgh-Of The Commonwealth System Of Higher Education	Analyse de cellules présentatrices d'antigène des lymphocytes b
EA027236B1 (ru)	2011-04-08	2017-07-31	Иммьюн Дизайн Корп.	Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
CN110339160A (zh)	2012-02-07	2019-10-18	传染性疾病研究院	包含tlr4激动剂的改进佐剂制剂及其使用方法
MX350274B (es)	2012-05-16	2017-08-31	Immune Design Corp	Vacunas para hsv-2.
CN109134640A (zh)	2012-10-23	2019-01-04	爱默蕾大学	Gm-csf和il-4轭合物、组合物以及与其相关的方法
BR112015025709A2 (pt)	2013-04-18	2017-07-18	Immune Design Corp	monoterapia com gla para uso em tratamento de câncer
US9463198B2 (en)	2013-06-04	2016-10-11	Infectious Disease Research Institute	Compositions and methods for reducing or preventing metastasis
CN106163551A (zh)	2013-12-31	2016-11-23	传染性疾病研究院	单瓶疫苗制剂
US10962534B2 (en)	2016-02-22	2021-03-30	Boehringer Ingelheim Vetmedica Gmbh	Method for the immobilization of biomolecules
WO2017200957A1 (fr)	2016-05-16	2017-11-23	Infectious Disease Research Institute	Liposomes pégylés et procédés d'utilisation
KR102392974B1 (ko)	2016-05-16	2022-05-02	인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이)	Tlr 작용제를 함유하는 제제 및 사용 방법
MX2021010105A (es)	2016-06-01	2022-06-16	Infectious Disease Res Inst	Particulas de nanoalumbre que contienen un agente de dimensionamiento.
CN111315362A (zh)	2017-06-15	2020-06-19	传染病研究所	纳米结构脂质载剂和稳定乳剂以及其用途
US20200276299A1 (en)	2017-09-08	2020-09-03	Infectious Disease Research Institute	Liposomal formulations comprising saponin and methods of use
US20220249646A1 (en)	2019-05-25	2022-08-11	Infectious Disease Research Institute	Composition and method for spray drying an adjuvant vaccine emulsion
WO2022051022A1 (fr)	2020-09-04	2022-03-10	Infectious Disease Research Institute	Arn co-lyophilisé et support lipidique nanostructuré
WO2024052882A1 (fr)	2022-09-09	2024-03-14	Access To Advanced Health Institute	Composition de vaccin immunogène incorporant une saponine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS57106626A (en) *	1980-12-22	1982-07-02	Teijin Ltd	Cytotoxic protein complex and its preparation
US4455296A (en) *	1982-02-02	1984-06-19	Board Of Regents, The University Of Texas System	Hybrid cell lines producing monoclonal antibodies directed against Haemophilus influenzae
US4671958A (en) *	1982-03-09	1987-06-09	Cytogen Corporation	Antibody conjugates for the delivery of compounds to target sites
FR2524487B1 (fr) *	1982-04-05	1985-11-22	Pasteur Institut	Fragments d'adn codant pour des polypeptides contenant au moins un determinant antigenique des papillomavirus, notamment du type hpv 1a et polypeptides correspondants
US4596674A (en) *	1984-09-11	1986-06-24	Merck & Co., Inc.	Immunogenic HAV peptides
DE3625257A1 (de) *	1986-07-23	1988-02-04	Behringwerke Ag	Expressionsprodukte der menschlichen papillomviren typ 16 und 18, fuer diese proteine spezifische antikoerper und diese antikoerper bzw. entsprechende dna enthaltende diagnostika
NZ223009A (en) *	1986-12-31	1990-06-26	Nl Rivm Of Thoven	Oligosaccharides containing d-ribose d-ribitol and phosphate units mimicing haemophilus influenzae type b antigens
EP0320942A3 (fr) *	1987-12-18	1989-10-04	American Cyanamid Company	Polysaccharides et composés macromoléculaires contenant ces polysaccharides
CA2038581A1 (fr) *	1990-03-20	1991-09-21	Martin Muller	Determinants antigeniques sereux des proteines 16 du virus des papillomes humains (vph)
ES2279020T3 (es) *	1991-07-19	2007-08-16	The University Of Queensland	Vacuna contra el papilomavirus humano.

1993
- 1993-06-24 PT PT93916789T patent/PT647140E/pt unknown
- 1993-06-24 ES ES93916789T patent/ES2294778T3/es not_active Expired - Lifetime
- 1993-06-24 DE DE122007000101C patent/DE122007000101I1/de active Pending
- 1993-06-24 DE DE122007000100C patent/DE122007000100I1/de active Pending
- 1993-06-24 WO PCT/US1993/006109 patent/WO1994000152A1/fr active IP Right Grant
- 1993-06-24 EP EP07013259A patent/EP1835029A1/fr not_active Withdrawn
- 1993-06-24 DE DE122007000095C patent/DE122007000095I1/de active Pending
- 1993-06-24 DE DE122007000099C patent/DE122007000099I1/de active Pending
- 1993-06-24 AT AT93916789T patent/ATE380871T1/de active
- 1993-06-24 DE DE122007000096C patent/DE122007000096I1/de active Pending
- 1993-06-24 DE DE122007000094C patent/DE122007000094I1/de active Pending
- 1993-06-24 DE DE69334192T patent/DE69334192T2/de not_active Expired - Lifetime
- 1993-06-24 DK DK93916789T patent/DK0647140T3/da active
- 1993-06-24 DE DE122007000097C patent/DE122007000097I1/de active Pending
- 1993-06-24 DE DE122007000098C patent/DE122007000098I1/de active Pending
- 1993-06-24 EP EP93916789A patent/EP0647140B1/fr not_active Expired - Lifetime
1995
- 1995-01-24 AU AU11352/95A patent/AU697743C/en not_active Expired
- 1995-06-07 US US08/473,228 patent/US20020068326A1/en not_active Abandoned
1996
- 1996-12-16 US US08/764,926 patent/US8012679B1/en not_active Expired - Fee Related
2005
- 2005-12-14 LU LU91395C patent/LU91395I2/fr unknown
2007
- 2007-12-14 NL NL300317C patent/NL300317I1/nl unknown
- 2007-12-14 LU LU91398C patent/LU91398I2/fr unknown
- 2007-12-14 LU LU91393C patent/LU91393I2/fr unknown
- 2007-12-14 NL NL300322C patent/NL300322I1/nl unknown
- 2007-12-14 NL NL300319C patent/NL300319I1/nl unknown
- 2007-12-14 LU LU91396C patent/LU91396I2/fr unknown
- 2007-12-14 LU LU91394C patent/LU91394I2/fr unknown
- 2007-12-14 LU LU91399C patent/LU91399I2/fr unknown
- 2007-12-14 NL NL300315C patent/NL300315I2/nl unknown
- 2007-12-14 LU LU91400C patent/LU91400I2/fr unknown
- 2007-12-14 NL NL300318C patent/NL300318I2/nl unknown
- 2007-12-14 NL NL300320C patent/NL300320I1/nl unknown
- 2007-12-14 NL NL300321C patent/NL300321I1/nl unknown
- 2007-12-14 LU LU91397C patent/LU91397I2/fr unknown
- 2007-12-14 NL NL300316C patent/NL300316I1/nl unknown
- 2007-12-21 FR FR07C0073C patent/FR07C0073I2/fr active Active

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8628784B2 (en) *	1998-10-16	2014-01-14	Glaxosmithkline Biologicals S.A.	Adjuvant systems and vaccines

Also Published As

Publication number	Publication date
AU1135295A (en)	1996-02-08
LU91393I2 (fr)	2008-02-14
EP1835029A1 (fr)	2007-09-19
LU91394I2 (fr)	2008-02-14
AU697743B2 (en)	1998-10-15
ES2294778T3 (es)	2008-04-01
LU91400I2 (fr)	2008-02-14
LU91396I2 (fr)	2008-02-14
DK0647140T3 (da)	2008-02-04
DE122007000099I1 (de)	2008-03-27
AU697743C (en)	2007-06-14
FR07C0073I2 (fr)	2012-08-03
DE69334192D1 (de)	2008-01-24
NL300319I1 (nl)	2008-03-03
LU91397I2 (fr)	2008-02-14
DE122007000095I1 (de)	2008-03-27
NL300318I2 (nl)	2008-03-03
PT647140E (pt)	2007-12-27
DE122007000094I1 (de)	2008-03-27
FR07C0073I1 (fr)	2008-01-02
NL300315I1 (nl)	2008-02-01
EP0647140A4 (fr)	1997-03-19
WO1994000152A1 (fr)	1994-01-06
DE122007000098I1 (de)	2008-03-27
NL300318I1 (nl)	2008-02-01
EP0647140A1 (fr)	1995-04-12
NL300320I1 (nl)	2008-03-03
LU91395I2 (fr)	2008-02-14
US8012679B1 (en)	2011-09-06
DE122007000100I1 (de)	2008-03-27
LU91398I2 (fr)	2008-02-14
NL300315I2 (nl)	2008-03-03
NL300321I1 (nl)	2008-03-03
DE122007000097I1 (de)	2008-03-27
DE122007000101I1 (de)	2008-03-27
EP0647140B1 (fr)	2007-12-12
LU91399I2 (fr)	2008-02-14
DE122007000096I1 (de)	2008-03-27
NL300316I1 (nl)	2008-02-01
NL300317I1 (nl)	2008-02-01
DE69334192T2 (de)	2008-12-04
ATE380871T1 (de)	2007-12-15
NL300322I1 (nl)	2008-03-03

Legal Events

Date	Code	Title	Description
2003-02-11	STCB	Information on status: application discontinuation	Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

Publication	Publication Date	Title
US8012679B1 (en)	2011-09-06	Papillomavirus vaccines
EP1015561B1 (fr)	2006-07-19	Methode de desassemblage-reassemblage in vitro de particules viroides (vlp) du papillomavirus
US7390487B2 (en)	2008-06-24	Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
US7220419B2 (en)	2007-05-22	Self-assembling recombinant papillomavirus capsid proteins
US6485728B2 (en)	2002-11-26	Formalin-Inactivated human papillomavirus L1 protein vaccine
US7279306B2 (en)	2007-10-09	Stable (fixed) forms of viral capsid proteins, and viral capsid protein fusions, preferably papillomavirus L1 proteins, and uses thereof
US6165471A (en)	2000-12-26	Homogeneous human papillomavirus capsomere containing compositions, methods for manufacture, and use thereof as diagnostic, prophylactic or therapeutic agents
US20040152181A1 (en)	2004-08-05	In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
AU755679B2 (en)	2002-12-19	Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture,and the use thereof as diagnostic, prophylactic or therapy
EP1250593B1 (fr)	2009-03-25	Methode de desassemblage-reassemblage in vitro de particules viroides (vlp) du papillomavirus
US6962777B1 (en)	2005-11-08	In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps), homogeneous vlp and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents
US20030096259A1 (en)	2003-05-22	In vitro method for disassembly/reassembly of papillomavirus virus-like particles (VLPs), homogeneous VLP and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents

US20020068326A1 - Papillomavirus vaccines - Google Patents

Info

Links

Images

Classifications

Priority Applications (1)

Applications Claiming Priority (3)

Related Parent Applications (1)

Publications (1)

Family

ID=25416951

Family Applications (2)

Family Applications After (1)

Country Status (12)

Cited By (1)

Families Citing this family (56)

Family Cites Families (10)

Cited By (1)

Also Published As

Similar Documents

Legal Events